Anavex Life Sciences Corp (AVXL)

[falconer66a]

Single drug; multiple therapies for multiple diseases.

They're running trials for multiple indications using THE EXACT SAME DRUG.

Yes, how often does this happen in clinical trials of candidate new drugs? Can anyone tell of another single drug that in recent times that with separate, distinct trials has been aimed at several different, diverse indications with simultaneous clinical trials for each?

For this to be the case, with the Anavex sigma-1 receptor agonists, particularly blarcamesine (Anavex 2-73) and Anavex 3.-71, those individual drugs must necessarily possess unique mechanisms of actions that moderate or restore normal, multiple downstream biochemistries that are otherwise pathogenic.

The two Anavex molecules fix things at the top, at the start of the various reaction pathways, obviating the otherwise consequent pathologies. Right now, the same drug, blarcamesine, is being clinically tested in humans who have a) Parkinson's disease dementia (PDD), b) Alzheimer's disease, and c) Rett syndrome. Each of these conditions is biologically separate, different, and unique. Rett syndrome is utterly different from Parkinson's disease dementia. By restoring the several functions of the activated sigma-1 receptor, the Anavex drugs can treat these three central nervous system (CNS) diseases.

Of course, right now the Anavex pipeline includes 10 different target conditions for the company's drugs. But sigma-1 receptor proteins are found in diverse cells and tissues throughout the human body. Presently, only CNS diseases are being targeted, but I'm certain that from murine (lab rodent) studies the company knows of a good number of other, non-CNS diseases or conditions for which their sigma-1 receptor agonists will have efficacy.

As someone some time ago mentioned, it's the iceberg phenomenon. Blarcamesine against PDD, Alzheimer's, and Rett can be seen above the clinical water level. But a lot more diseases and conditions presently out of view will be eventually tested with the Anavex drugs. First things first; some big CNS diseases. After those, 21st-century medicine could be dramatically altered and improved for many other conditions. Let's watch.